Pharmathen has best-in-class R&D capabilities, resulting in an extensive pipeline of around 40 products across five technology platforms: complex oral solids, ophthalmics, injectables, long-acting injectables, and peptides. Pharmathen has a differentiated B2B model and serves over 250 customers from its US- and EU-approved manufacturing facilities. The company’s products are accessed by patients in more than 90 countries.
Thematic conviction
Pharmathen is benefiting from growing outsourcing trends amongst major pharmaceutical companies. Demand for drug delivery specialists is set to remain robust as pharmaceutical companies seek to manage costs, risks, and internal capacity and capabilities constraints whilst offering increasingly complex products.
Business building
Partners Group is working closely with Pharmathen's management team to scale the business. Key value creation initiatives include building and converting on the company's strong pipeline of products, accelerating expansion in the US, and completing strategic acquisitions to add new technologies and scale the core.
